



DECEMBER 16, 2015

Pages (inc this Page) 3

ASX Market Announcements
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

RE: William (Bill) Hunter MD to Join the Adherium Board

The Company is delighted to announce that Angiotech founder and life sciences entrepreneur Dr William (Bill) Hunter has agreed to join the Adherium Board.

More details regarding Dr Hunter's background can be found in the attached announcement.

Kind regards

Bronwyn Le Grice
Joint Company Secretary

[ASX: ADR](#)

Company Overview

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

Directors

Dr J Doug Wilson (Chair)
Mr Garth Sutherland (Group CEO)
Prof. John Mills
Mr Jeremy Curnock Cook
Mr Bruce McHarrie
Mr Bryan Mogridge

Joint Company Secretaries

Mr Rob Turnbull
Ms Bronwyn Le Grice

Registered Office

L12, 15 William Street
Melbourne VIC 3000
Australia

New Zealand Office

L2, 204 Quay Street
Auckland 1010
New Zealand

Investor Relations Contact

Ms Bronwyn Le Grice
+61 424 862 600

Email

investors@adherium.com

Website

www.adherium.com

For personal use only

William (Bill) Hunter MD to Join Adherium Board

Melbourne, Australia, 16 December 2015: Adherium Limited (ASX: ADR), a global leader in digital health technologies addressing sub-optimal medication use in chronic disease, today confirmed that Canada-based pharmaceutical entrepreneur William (Bill) Hunter MD has agreed to join the Adherium Board as a non-executive director.

Dr Hunter is currently the President and CEO of renowned Cardiome Pharma Corp (NASDAQ: CRME) based in Vancouver, Canada. Cardiome is a specialty pharmaceutical company with three cardiology products approved in Europe and globally. Under Dr Hunter's leadership, Cardiome has built its own direct sales force in Europe, acquired another company and product, assembled an international distribution network and in-licensed three additional products leading to an increase in Cardiome's valuation beyond \$200m.

Having made a career out of inventing and improving medical devices, Dr Hunter has 200 patents and patent applications to his name and has been involved in the discovery and development of several key devices and products used in over 10 million patients with total revenues exceeding \$12 billion.

His latest venture, Canary Medical, utilises sensor technology to allow implanted medical devices to "self-report" on function, activity, wear, complications and patient outcomes, and in the analysis of the data generated by those devices.

While still in medical school, Dr Hunter co-founded Angiotech Pharmaceuticals. After becoming CEO and President of Angiotech he led the company through three rounds of private equity financing, IPO stage and listing on the Toronto Stock Exchange and NASDAQ, over \$1b in equity and debt financings, a debt restructuring and eight separate corporate acquisitions. Worldwide annual revenues exceeded \$250m.

"Bill has an impressive history commercialising medical devices. He is a major asset for the Adherium boardroom as we escalate international commercialisation of our products and services," said Adherium Chairman Doug Wilson.

Dr Hunter is currently a director of Epirus Biopharmaceuticals Inc (NASDAQ: EPRS), Rex Bionics (AIM: RXB) as well as Cardiome. He has been awarded with the 2006 Principal Award from the Manning Foundation (one of Canada's highest awards for innovation); BC Innovation Council's Cecil Green Award for Science and Technology Entrepreneurship; Entrepreneur of the Year from the Canadian Venture Capital and Private Equity Association; and Canada's 40 Under 40. He has a BSc from McGill University and a MSc and MD degree from the University of British Columbia.

****ENDS****

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium has the broadest range of "smart" medication sensors for respiratory medications globally. Adherium Smartinhaler™ medication sensors attach to prescription inhalers to provide reminders and monitoring of inhaler usage.

The SmartinhalerLive™ platform uses wireless communications technology to provide real time data collection and reporting from Smartinhaler™ medication sensors.

Clinical outcomes data has proven that the Smartinhaler platform can improve adherence by up to 59% in adults and 180% in children with asthma. In addition, severe episodes were reduced by 60% in adults with asthma. Both groups benefited from improved quality-of-life as a result of their improved adherence, demonstrating a substantial gain over current best practice treatment.

The Smartinhaler™ platform has so far been used in 40 projects (clinical, device validation or other) and has peer reviewed clinical outcomes data resulting from 14 studies. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations.

www.adherium.com

At the Company	Media enquiries
<p>Bronwyn Le Grice Head of Commercial Development & Corporate Affairs M +61 (0)424 862 600 E: bronwynlg@adherium.com</p>	<p>EU Media Sue Charles / Gemma Howe Instinctif Partners D +44 (0)20 7866 7860 E: +44 20 7866 7860</p> <p>AU/NZ/ Media Rudi Michelson Monsoon Communications D +61 (0)3 9620 3333 E rudim@monsoon.com.au</p>

For personal use only